Cumberland Pharmaceuticals receives FDA Fast Track Designation for Ifetroban Duchenne Muscular Dystrophy Program.

Cumberland Pharmaceuticals has received FDA Fast Track Designation for its oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The designation provides more frequent communication with the FDA and an expedited review process. Cumberland's ifetroban has previously demonstrated a 5.4% improvement in left ventricular ejection fraction in a Phase 2 trial. This is a significant milestone in the development of a much-needed therapy for DMD patients.